The estimated Net Worth of Frank Mccormick is at least $29.8 Milion dollars as of 26 December 2023. Frank Mccormick owns over 100,000 units of BridgeBio Pharma Inc stock worth over $17,569,015 and over the last 21 years he sold BBIO stock worth over $12,237,000. In addition, he makes $0 as Chairman of Oncology at BridgeBio Pharma Inc.
Frank has made over 3 trades of the BridgeBio Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 100,000 units of BBIO stock worth $4,206,000 on 26 December 2023.
The largest trade he's ever made was selling 100,000 units of BridgeBio Pharma Inc stock on 26 December 2023 worth over $4,206,000. On average, Frank trades about 11,538 units every 56 days since 2003. As of 26 December 2023 he still owns at least 627,689 units of BridgeBio Pharma Inc stock.
You can see the complete history of Frank Mccormick stock trades at the bottom of the page.
Dr. Frank Mccormick Ph.D. serves as Chairman of Oncology of the Company. Dr. McCormick has held the positions of Director the UCSF Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization and served as Associate Dean of the UCSF School of Medicine from 1997 to 2014. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991, and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992, Dr. McCormick founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham, and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996, a member of the National Academy of Sciences since 2014 and has served as President, 2012 to 2013, for the American Association for Cancer Research. Since 2013, Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers.
Frank Mccormick is 69, he's been the Chairman of Oncology of BridgeBio Pharma Inc since 2019. There are 2 older and 20 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Frank's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo a Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: